Key Drivers
- Strong FCF
- Meaningful leverage
- Modest net margin
AIAI Summary
FMS has shifted from a steady defensive cash-generator to a near-term, execution-driven value bet where buybacks/dividends and FME25+ cost savings are propping up per‑share metrics even as 2026 looks like a volatile transition year with flat revenues and heavy launch/divestiture activity. Actionable focus: watch realization of FME25+ savings versus U.S. treatment volumes and any credible pace of debt reduction—if savings sustain and volumes normalize, the stock is attractively priced; if not, leverage and launch costs could quickly erode the apparent value.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong FCF
- •Meaningful leverage
- •Modest net margin
FMS delivers strong cash generation, solid operating margins and an attractive trailing valuation and dividend yield, but meaningful net debt, large intangibles and modest net margins raise financial risk if earnings weaken.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Defended 22.6–23.5
- •Resistance 24.3–24.6
FMS is tilted negative—trading about 6% below its last month simple moving average (~$23.05) with $21.64 as the period low, support near $22.60–$22.80, resistance at $24.30–$24.60, and a decisive close below $21.64 would raise downside risk.
Orderly decline from ~$24.59 in late
Sentiment & News
Key News Insights:
- •Strong margins
- •Capital returns
- •Mixed outlook
Fresenius Medical Care delivered strong 2025 results with double‑digit margin and EPS expansion driven by cost savings and buybacks, but a cautious outlook and weaker U.S. performance triggered near‑term share volatility.
Results and buybacks support a more constructive long‑term case, but near‑term stock performance will likely remain volatile due to geographic weaknesses and guidance concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings